What starts as breathlessness can turn fatal within minutes, doctors warn that quick action, correct inhaler use and timely ...

SAVING’ jab for severe asthma that could prevent deadly attacks with just two doses a year could be available to patients in ...

The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.

The U.S. Food and Drug Administration has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for severe ...

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

Marketed as Exdensur, the ultra-long-acting biologic is the first of its kind, requiring only two injections per year to ...

Tezepelumab may allow patients with severe, uncontrolled asthma who are oral corticosteroid-dependent to decrease their OCS use.

The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...

Asthma isn’t always a quick and easy diagnosis in children. According to a 2014 task force assembled by the American Thoracic Society and the European Respiratory Society, pediatric severe asthma can ...

Registry-based data indicate that comorbid sleep disorders are common in severe asthma and are associated with significantly ...

More must be done to ensure that asthma patients get access to cutting-edge treatments, experts have said, after research ...